FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149026055> ?p ?o ?g. }

• W2149026055 endingPage "2512" @default.
• W2149026055 startingPage "2505" @default.
• W2149026055 abstract "Purpose This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculature, on tumor growth in patients with metastatic renal cell carcinoma. Patients and Methods Patients initially received oral sorafenib 400 mg twice daily during the initial run-in period. After 12 weeks, patients with changes in bidimensional tumor measurements that were less than 25% from baseline were randomly assigned to sorafenib or placebo for an additional 12 weeks; patients with ≥ 25% tumor shrinkage continued open-label sorafenib; patients with ≥ 25% tumor growth discontinued treatment. The primary end point was the percentage of randomly assigned patients remaining progression free at 24 weeks after the initiation of sorafenib. Results Of 202 patients treated during the run-in period, 73 patients had tumor shrinkage of ≥ 25%. Sixty-five patients with stable disease at 12 weeks were randomly assigned to sorafenib (n = 32) or placebo (n = 33). At 24 weeks, 50% of the sorafenib-treated patients were progression free versus 18% of the placebo-treated patients (P = .0077). Median progression-free survival (PFS) from randomization was significantly longer with sorafenib (24 weeks) than placebo (6 weeks; P = .0087). Median overall PFS was 29 weeks for the entire renal cell carcinoma population (n = 202). Sorafenib was readministered in 28 patients whose disease progressed on placebo; these patients continued on sorafenib until further progression, for a median of 24 weeks. Common adverse events were skin rash/desquamation, hand-foot skin reaction, and fatigue; 9% of patients discontinued therapy, and no patients died from toxicity. Conclusion Sorafenib has significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with chronic daily therapy." @default.
• W2149026055 created "2016-06-24" @default.
• W2149026055 creator A5007801126 @default.
• W2149026055 creator A5011905014 @default.
• W2149026055 creator A5014285115 @default.
• W2149026055 creator A5014804968 @default.
• W2149026055 creator A5019320471 @default.
• W2149026055 creator A5023174631 @default.
• W2149026055 creator A5028533192 @default.
• W2149026055 creator A5031338691 @default.
• W2149026055 creator A5033091020 @default.
• W2149026055 creator A5045588447 @default.
• W2149026055 creator A5063293745 @default.
• W2149026055 creator A5068268371 @default.
• W2149026055 creator A5070570779 @default.
• W2149026055 creator A5071903899 @default.
• W2149026055 creator A5087376683 @default.
• W2149026055 creator A5088131964 @default.
• W2149026055 date "2006-06-01" @default.
• W2149026055 modified "2023-10-14" @default.
• W2149026055 title "Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma" @default.
• W2149026055 cites W1968562111 @default.
• W2149026055 cites W1985558960 @default.
• W2149026055 cites W1986094466 @default.
• W2149026055 cites W1989584976 @default.
• W2149026055 cites W2008863591 @default.
• W2149026055 cites W2013321025 @default.
• W2149026055 cites W2018348203 @default.
• W2149026055 cites W2018879787 @default.
• W2149026055 cites W2046507292 @default.
• W2149026055 cites W2047198790 @default.
• W2149026055 cites W2049884397 @default.
• W2149026055 cites W2052550764 @default.
• W2149026055 cites W2053146576 @default.
• W2149026055 cites W2073680312 @default.
• W2149026055 cites W2099259685 @default.
• W2149026055 cites W2099833638 @default.
• W2149026055 cites W2106453307 @default.
• W2149026055 cites W2116177733 @default.
• W2149026055 cites W2136782239 @default.
• W2149026055 cites W2140765540 @default.
• W2149026055 cites W2143813821 @default.
• W2149026055 cites W2152618785 @default.
• W2149026055 cites W2162439819 @default.
• W2149026055 cites W2163188200 @default.
• W2149026055 cites W2166271687 @default.
• W2149026055 cites W2167805334 @default.
• W2149026055 cites W2305352133 @default.
• W2149026055 cites W2341616998 @default.
• W2149026055 doi "https://doi.org/10.1200/jco.2005.03.6723" @default.
• W2149026055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16636341" @default.
• W2149026055 hasPublicationYear "2006" @default.
• W2149026055 type Work @default.
• W2149026055 sameAs 2149026055 @default.
• W2149026055 citedByCount "965" @default.
• W2149026055 countsByYear W21490260552012 @default.
• W2149026055 countsByYear W21490260552013 @default.
• W2149026055 countsByYear W21490260552014 @default.
• W2149026055 countsByYear W21490260552015 @default.
• W2149026055 countsByYear W21490260552016 @default.
• W2149026055 countsByYear W21490260552017 @default.
• W2149026055 countsByYear W21490260552018 @default.
• W2149026055 countsByYear W21490260552019 @default.
• W2149026055 countsByYear W21490260552020 @default.
• W2149026055 countsByYear W21490260552021 @default.
• W2149026055 countsByYear W21490260552022 @default.
• W2149026055 countsByYear W21490260552023 @default.
• W2149026055 crossrefType "journal-article" @default.
• W2149026055 hasAuthorship W2149026055A5007801126 @default.
• W2149026055 hasAuthorship W2149026055A5011905014 @default.
• W2149026055 hasAuthorship W2149026055A5014285115 @default.
• W2149026055 hasAuthorship W2149026055A5014804968 @default.
• W2149026055 hasAuthorship W2149026055A5019320471 @default.
• W2149026055 hasAuthorship W2149026055A5023174631 @default.
• W2149026055 hasAuthorship W2149026055A5028533192 @default.
• W2149026055 hasAuthorship W2149026055A5031338691 @default.
• W2149026055 hasAuthorship W2149026055A5033091020 @default.
• W2149026055 hasAuthorship W2149026055A5045588447 @default.
• W2149026055 hasAuthorship W2149026055A5063293745 @default.
• W2149026055 hasAuthorship W2149026055A5068268371 @default.
• W2149026055 hasAuthorship W2149026055A5070570779 @default.
• W2149026055 hasAuthorship W2149026055A5071903899 @default.
• W2149026055 hasAuthorship W2149026055A5087376683 @default.
• W2149026055 hasAuthorship W2149026055A5088131964 @default.
• W2149026055 hasBestOaLocation W21490260551 @default.
• W2149026055 hasConcept C126322002 @default.
• W2149026055 hasConcept C126894567 @default.
• W2149026055 hasConcept C141071460 @default.
• W2149026055 hasConcept C142724271 @default.
• W2149026055 hasConcept C143998085 @default.
• W2149026055 hasConcept C168563851 @default.
• W2149026055 hasConcept C197934379 @default.
• W2149026055 hasConcept C203092338 @default.
• W2149026055 hasConcept C204243189 @default.
• W2149026055 hasConcept C204787440 @default.
• W2149026055 hasConcept C27081682 @default.
• W2149026055 hasConcept C2777472916 @default.
• W2149026055 hasConcept C2778019345 @default.

• next